Paul G Richardson, MD
Bisht K et al. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med 2023;12(20):20332-52. Abstract
Chhabra S et al. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: Findings from the MASTER and GRIFFIN trials. Transplant Cell Ther 2023;29(3):174.e1-10. Abstract
Costa LJ et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): Final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol 2023;10(11):e890-901. Abstract
Costa LJ et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40(25):2901-12. Abstract
Dytfeld D et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): Interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(2):139-50. Abstract
Facon T et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA. Leukemia 2022;36(4):1066-77. Abstract
Facon T et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: Ikema subgroup analysis. Blood 2022;140(suppl 1):1820-2. Abstract
Gay F et al. Results of the phase III randomized iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. ASH 2023;Abstract 4.
Giri S et al. Quadruplet induction, autologous transplantation and minimal residual disease adapted consolidation and treatment cessation in older adults ≥70y with newly diagnosed multiple myeloma: A subgroup analysis of the master trial. Blood 2022;140(suppl 1):4431-3. Abstract
Leypoldt LB et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 2023;[Online ahead of print]. Abstract
Martino EA et al. Isatuximab in multiple myeloma. Expert Opin Biol Ther 2023;23(4):315-8. Abstract
Mateos M-V et al. GEM2017FIT trial: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: Phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. ASH 2023;Abstract 209.
Ocio EM et al. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia 2023;37(7):1521-9. Abstract
Ocio EM et al. Phase 1b study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients. Hemasphere 2023;7(2):e829. Abstract
San-Miguel J et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 2022;139(4):492-501. Abstract
Sonneveld P et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus vrd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): Primary results of the perseus trial. ASH 2023;Abstract LBA-1.
Touzeau C et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: Final results of the phase 2 study IFM 2018-04. ASH 2023;Abstract 207.
Voorhees PM et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10(10):e825-37. Abstract
Sagar Lonial, MD
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J 2023;13(1):72. Abstract
Moreau P et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): Final overall survival analysis. IMS 2023;Abstract OA-48.
Moreau P et al. Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (isa-kd) vs kd in relapsed multiple myeloma (MM). ESMO Virtual Plenary 2022;Abstract VP5-2022.
Quach H et al. Carfilzomib use among patients with relapsed/refractory multiple myeloma in the Asia Pacific region: Characteristics and outcomes by regimen from a prospective, real-world study. ASH 2022;Abstract 1923.
Richardson PG et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3):416. Abstract
Richardson PG et al. Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): Final overall survival analysis. IMS 2022;Abstract OAB-052.
Spicka I et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol 2022;109(5):504-12. Abstract
Noopur Raje, MD
Agha ME et al. CARTITUDE-2 cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. EHA 2022;Abstract S185.
Bal S et al. Clinical activity of BMS-986393 (CC-95266), a G protein-couples receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): First results from a phase 2, multicenter, open-label study. ASH 2022;Abstract 364.
Cohen AD et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12:32. Abstract
Frigault MJ et al. Phase 1 Study of CART-Ddbcma for the treatment of patients with relapsed and/or refractory multiple myeloma: Results from at least 1-year follow-up in all patients. ASH 2023;Abstract 1023.
Hillengass J et al. Ciltacabtagene autoleucel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 biological correlative analyses and updated clinical data. EHA 2022;Abstract P959.
Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388(11):1002-14. Abstract
San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract
Amrita Krishnan, MD
Carlo-Stella C et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood 2022;140(Supplement 1):397-9. Abstract
Chari A et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts): Final analysis of Griffin among clinically relevant subgroups. ASH 2022;Abstract 157.
Firestone R et al. Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies. ASCO 2023;Abstract 8049.
Kegyes D et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol 2022;15(1):78. Abstract
Lee HC et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. ASCO 2023;ASCO 8006.
Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259-67. Abstract
Nooka AK et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. ASCO 2023;Abstract 8008.
Schinke CD et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8036.
van de Donk NWCJ et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8011.
Robert Z Orlowski, MD, PhD
Bahlis NJ et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 2021;39(32):3602-12. Abstract
Costa LJ et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv 2021;5(19):3748-59. Abstract
Lonial S et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022;9(11):e822-32. Abstract
Mateos M-V et al. Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. IMS 2023;Abstract OA-52.
Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract